Cargando…
Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer
A prospective study was performed in patients with non-small cell lung cancer (NSCLC) to evaluate the prognostic importance of multiple molecular marker (p53, c-Ki-ras, c-erbB-2) testing. 103 patients with potentially curative resections (RO resection) for NSCLC in histopathological stages I–IIIA we...
Autores principales: | Schneider, P M, Praeuer, H W, Stoeltzing, O, Boehm, J, Manning, J, Metzger, R, Fink, U, Wegerer, S, Hoelscher, A H, Roth, J A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374666/ https://www.ncbi.nlm.nih.gov/pubmed/10945494 http://dx.doi.org/10.1054/bjoc.2000.1287 |
Ejemplares similares
-
Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer
por: Miyazono, F, et al.
Publicado: (2004) -
Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988) -
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
por: Archer, S. G., et al.
Publicado: (1995) -
C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis.
por: Parkes, H. C., et al.
Publicado: (1990) -
Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice.
por: Mehta, R. R., et al.
Publicado: (1995)